Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027780) ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/027780 International Application No.: PCT/US2018/043827
Publication Date: 07.02.2019 International Filing Date: 26.07.2018
IPC:
C07K 16/24 (2006.01) ,C07K 16/28 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285, US
Inventors:
BOYLES, Jeffrey S.; US
CHAI, Qing; US
DEMAREST, Stephen J.; US
NA, Songqing; US
Agent:
MARKS, Duane C.; US
COMBS, Tonya L.; US
Priority Data:
62/540,18202.08.2017US
Title (EN) ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES
(FR) ANTICORPS BISPÉCIFIQUES D'IGG ANTI-TNF- / ANTI-IL-23
Abstract:
(EN) IgG bispecific antibodies are provided that bind tumor necrosis factor alpha (TNFa) and the pl9 subunit of interleukin-23 (IL-23pl9) and are characterized as having high affinity and simultaneous neutralizing properties to both TNFa and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, and Hidradenitis suppurativa.
(FR) L'invention concerne des anticorps bispécifiques d'IgG qui se lient au facteur alpha de nécrose tumorale (TNFa) et à la sous-unité pl9 de l'interleukine-23 (IL-23pl9) et qui se caractérisent par leur affinité élevée et leurs propriétés de neutralisation simultanée, à la fois de TNFa et de IL-23. Les anticorps bispécifiques selon la présente invention sont utiles pour traiter diverses maladies auto-immunes, y compris la maladie intestinale inflammatoire, telle que la maladie de Crohn et la colite ulcéreuse, le psoriasis, le rhumatisme psoriasique et l'hidradénite suppurée.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)